Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

By  

Current Cancer Drug Targets, Vol. 11, Iss. 3, 2011-03 ,pp. : 239-253

Bentham Science Publishers

Access to resources Recommend Favorite

Current pharmacotherapeutical options for the prevention of kidney transplant rejection

By Schaefer Sebastian M   Süsal Caner   Sommerer Claudia   Zeier Martin   Morath Christian  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 8, 2013-06 ,pp. : 1029-1041

Informa Healthcare

Access to resources Recommend Favorite

Long-term use of ciclosporin on kidney transplant recipients surviving more than 10 years

By Qin Yan   Fan Yu   Mu Xingyu   Zhang Fang   Shen Bing   Liu Yong   Guo Yifeng   Wang Yong   Qiu Jianxin  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 69, Iss. 7, 2014-07 ,pp. : 558-560

Govi-Verlag

Access to resources Recommend Favorite

Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives

By Cattaneo Dario   Baldelli Sara   Merlini Simona   Zenoni Stefania   Perico Norberto   Remuzzi Giuseppe  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 11, 2004-11 ,pp. : 1553-1566

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib: A Review of its Use in Patients with Multiple Myeloma

By Curran Monique P.   McKeage Kate  

Drugs, Vol. 69, Iss. 7, 2009-05 ,pp. : 859-888

Adis International

Access to resources Recommend Favorite